CA3046350C - Glyceryl 3-hydroxybutyrates for migraine symptom management - Google Patents
Glyceryl 3-hydroxybutyrates for migraine symptom management Download PDFInfo
- Publication number
- CA3046350C CA3046350C CA3046350A CA3046350A CA3046350C CA 3046350 C CA3046350 C CA 3046350C CA 3046350 A CA3046350 A CA 3046350A CA 3046350 A CA3046350 A CA 3046350A CA 3046350 C CA3046350 C CA 3046350C
- Authority
- CA
- Canada
- Prior art keywords
- mivi
- hydroxybutyrate
- glyceryl
- migraine
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000019695 Migraine disease Diseases 0.000 title claims abstract description 109
- 206010027599 migraine Diseases 0.000 title claims abstract description 91
- 208000024891 symptom Diseases 0.000 title claims abstract description 44
- CBTHKODKAPVTNY-UHFFFAOYSA-N 2,3-dihydroxypropyl 3-hydroxybutanoate Chemical class CC(O)CC(=O)OCC(O)CO CBTHKODKAPVTNY-UHFFFAOYSA-N 0.000 title claims description 4
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 claims abstract description 45
- WHBMMWSBFZVSSR-UHFFFAOYSA-N R3HBA Natural products CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims abstract description 36
- -1 glyceryl 3-hydroxybutyrate ester compound Chemical class 0.000 claims abstract description 35
- 150000002576 ketones Chemical class 0.000 claims abstract description 20
- 230000037058 blood plasma level Effects 0.000 claims abstract description 14
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 claims abstract description 11
- 239000007983 Tris buffer Substances 0.000 claims description 33
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 25
- 150000002148 esters Chemical class 0.000 claims description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 20
- 230000003252 repetitive effect Effects 0.000 claims description 18
- 206010019233 Headaches Diseases 0.000 claims description 16
- 231100000869 headache Toxicity 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 230000001684 chronic effect Effects 0.000 claims description 14
- 230000037396 body weight Effects 0.000 claims description 10
- 230000001667 episodic effect Effects 0.000 claims description 10
- 208000037048 Prodromal Symptoms Diseases 0.000 claims description 6
- 230000037406 food intake Effects 0.000 claims 12
- 101100191244 Caenorhabditis elegans pph-6 gene Proteins 0.000 claims 4
- 230000007062 hydrolysis Effects 0.000 claims 4
- 238000006460 hydrolysis reaction Methods 0.000 claims 4
- WHBMMWSBFZVSSR-GSVOUGTGSA-M (R)-3-hydroxybutyrate Chemical compound C[C@@H](O)CC([O-])=O WHBMMWSBFZVSSR-GSVOUGTGSA-M 0.000 claims 1
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical group CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 17
- 235000020887 ketogenic diet Nutrition 0.000 description 22
- 238000011282 treatment Methods 0.000 description 19
- 239000000194 fatty acid Substances 0.000 description 8
- 206010027603 Migraine headaches Diseases 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- 230000001376 precipitating effect Effects 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 230000036765 blood level Effects 0.000 description 6
- 229960003133 ergot alkaloid Drugs 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 238000002651 drug therapy Methods 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- 206010015037 epilepsy Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000003642 hunger Nutrition 0.000 description 3
- 230000035861 hyperketonemia Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 150000004667 medium chain fatty acids Chemical class 0.000 description 3
- 229940057917 medium chain triglycerides Drugs 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000037351 starvation Effects 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 208000007976 Ketosis Diseases 0.000 description 2
- 206010034960 Photophobia Diseases 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
- 206010000410 Acetonaemia Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- AOWPVIWVMWUSBD-RNFRBKRXSA-N [(3r)-3-hydroxybutyl] (3r)-3-hydroxybutanoate Chemical compound C[C@@H](O)CCOC(=O)C[C@@H](C)O AOWPVIWVMWUSBD-RNFRBKRXSA-N 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007585 cortical function Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000004140 ketosis Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 235000021084 monounsaturated fats Nutrition 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007996 neuronal plasticity Effects 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021085 polyunsaturated fats Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 230000003238 somatosensory effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/389,828 US20180177753A1 (en) | 2016-12-23 | 2016-12-23 | Glyceryl 3-hydroxybutyrates for migraine symptom management |
| US15/389,828 | 2016-12-23 | ||
| PCT/US2017/063832 WO2018118369A1 (en) | 2016-12-23 | 2017-11-30 | Glyceryl 3-hydroxybutyrates for migraine symptom management |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3046350A1 CA3046350A1 (en) | 2018-06-28 |
| CA3046350C true CA3046350C (en) | 2022-08-16 |
Family
ID=62624821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3046350A Active CA3046350C (en) | 2016-12-23 | 2017-11-30 | Glyceryl 3-hydroxybutyrates for migraine symptom management |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20180177753A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3558458B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7108320B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102390608B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110167637B (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019012431A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3046350C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2962879T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL267540B (cg-RX-API-DMAC7.html) |
| MX (1) | MX389468B (cg-RX-API-DMAC7.html) |
| MY (1) | MY190308A (cg-RX-API-DMAC7.html) |
| PT (1) | PT3558458T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018118369A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11241403B2 (en) | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
| US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
| US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
| US12109182B2 (en) | 2016-04-19 | 2024-10-08 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
| US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
| US12329734B2 (en) | 2017-12-19 | 2025-06-17 | Axcess Global Sciences, Llc | Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow |
| US12496283B2 (en) | 2016-04-19 | 2025-12-16 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| DK3558280T3 (da) | 2016-12-21 | 2023-08-21 | Univ Kinderspital Beider Basel | Forebyggelse og behandling af migræne |
| US10376528B2 (en) | 2017-03-10 | 2019-08-13 | Tecton Group, Llc | Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor |
| GB201715654D0 (en) | 2017-09-27 | 2017-11-08 | Tdeltas Ltd | Method of treatment |
| US12090129B2 (en) | 2017-11-22 | 2024-09-17 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| EP3880650B1 (de) * | 2019-01-17 | 2023-09-06 | KetoLipix Therapeutics GmbH | Verfahren zur herstellung von struktureinheiten auf basis von glyceriden von hydroxycarbonsäuren enthaltenden lipiden |
| CN113329990B (zh) * | 2019-01-17 | 2024-06-07 | 凯托利皮克斯治疗有限责任公司 | 羟基羧酸甘油酯的生产方法 |
| BR112021017954A2 (pt) | 2019-03-14 | 2021-11-16 | Neuroenergy Ventures Inc | Formulação de mascaramento de sabor para compostos de corpo cetônico |
| US12472200B2 (en) | 2019-05-15 | 2025-11-18 | Axcess Global Sciences, Llc | Autobiotic compositions and method for promoting healthy gut microbiome |
| WO2020242478A1 (en) * | 2019-05-30 | 2020-12-03 | Neuroenergy Ventures, Inc. | Glyceryl tris (beta-hydroxybutyrate) and neuronal transient ischemic attacks |
| US20250197566A1 (en) * | 2019-06-12 | 2025-06-19 | Ioi Oleo Gmbh | Process for preparing polyol-based esters of acyl-capped hydroxy carboxylic acids |
| US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
| US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US12167993B2 (en) | 2019-06-21 | 2024-12-17 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| IT201900018491A1 (it) * | 2019-10-10 | 2021-04-10 | Dr Schaer S P A | Procedimento di purificazione del tris-(3-idrossibutirrato)-gliceril estere |
| IT201900018488A1 (it) * | 2019-10-10 | 2021-04-10 | Dr Schaer S P A | Procedimento di preparazione del tris-(3-idrossibutirrato)-gliceril estere |
| US12186297B2 (en) | 2020-08-26 | 2025-01-07 | Axcess Global Sciences, Llc | Compositions and methods for increasing lean-to-fat mass ratio |
| AU2022387742A1 (en) * | 2021-11-12 | 2024-06-27 | Arxada Ag | Polyol-derived compounds |
| US20250002446A1 (en) * | 2021-11-26 | 2025-01-02 | Arxada Ag | Acetoacetate Based Ketals |
| US20240299548A1 (en) * | 2022-01-18 | 2024-09-12 | Today, Inc. | Molecules, formulations, and methods for nutritional support of athletes, patients, and others |
| US12023382B2 (en) | 2022-01-18 | 2024-07-02 | Today Inc. | Molecules, formulations, and methods for nutritional support of athletes, patients, and others |
| WO2024083889A1 (en) | 2022-10-18 | 2024-04-25 | Arxada Ag | Polyol-derived compounds |
| WO2025074001A2 (en) | 2023-10-05 | 2025-04-10 | Arxada Ag | Enzymatic reduction of acetoacetate |
| WO2025196156A1 (en) | 2024-03-20 | 2025-09-25 | Arxada Ag | Continuous hydrogenation process of acetoacetate esters |
| WO2025224319A1 (en) | 2024-04-25 | 2025-10-30 | Arxada Ag | Reduction of acetoacetate esters in the presence of amines |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420856D0 (en) * | 2004-09-20 | 2004-10-20 | Ketocytonyx Inc | Cns modulators |
| HUE035852T2 (en) | 2006-04-03 | 2018-05-28 | Accera Inc | Use of ketogen compounds to treat memory decline |
| WO2008005818A1 (en) * | 2006-06-30 | 2008-01-10 | Stepan Co | Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose |
| BRPI1005372A2 (pt) * | 2009-01-24 | 2018-03-06 | Phytopharm Plc | metodo de indução da homeostase- regulada de fatores neurotroficos agente; composição; e; uso de um ou mais agentes selecionados de saponinas esteroidais de a/b-cis furostano, furosteno espirostano e espirosteno, e as suas formas de eter, cetona e glicosiladas |
| CA2873057C (en) | 2011-05-09 | 2020-02-25 | University Of South Florida | The use of ketone esters for prevention of cns oxygen toxicity |
| US20140072654A1 (en) | 2011-12-23 | 2014-03-13 | Savind, Inc. | Cancer with metabolic therapy and hyperbaric oxygen |
| FR2997302B1 (fr) * | 2012-10-29 | 2015-02-06 | Assist Publ Hopitaux De Paris | Prevention et traitement des deficits en pyruvate deshydrogenase |
| ES2752030T3 (es) | 2012-11-05 | 2020-04-02 | Us Health | Cuerpos cetónicos para proteger los tejidos del daño por radiación ionizante |
| EP2925308B1 (en) | 2012-11-28 | 2019-12-25 | University Of South Florida | Targeting cancer with metabolic therapy and hyperbaric oxygen |
| WO2014153416A1 (en) | 2013-03-19 | 2014-09-25 | University Of South Florida | Compositions and methods for producing elevated and sustained ketosis |
| GB201314127D0 (en) * | 2013-08-07 | 2013-09-18 | Tdeltas Ltd | Ketone body and ketone body ester for reducing muscle breakdown |
| EP3549928B1 (en) | 2014-01-13 | 2021-09-22 | University of South Florida | Methods of sustaining dietary ketosis and its effects on muscle fatigue |
| US20160078782A1 (en) * | 2014-09-17 | 2016-03-17 | The Trustees Of Boston College | Glucose Ketone Index for MetabolicTherapy |
| US9364456B1 (en) | 2015-06-30 | 2016-06-14 | University Of South Florida | Ketone esters for treatment of angelman syndrome |
| WO2017011294A1 (en) | 2015-07-10 | 2017-01-19 | Cognate Nutritionals, Inc. | Prophylaxis and mitigation of migraine headaches using medium chain triglycerides, ketone esters, and other ketogenic sources |
| US10292952B2 (en) | 2016-03-11 | 2019-05-21 | Axcess Global Sciences, Llc | Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis |
| US10376482B2 (en) | 2016-04-03 | 2019-08-13 | Franco Cavaleri | Butyrate and beta-hydroxybutyrate compositions |
| SG11201809211QA (en) | 2016-04-19 | 2018-11-29 | Keto Patent Group Inc | Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans |
| WO2018009208A1 (en) | 2016-07-08 | 2018-01-11 | Cognate Nutritionals, Inc. | Nutritional mitiggation of the cns effects of traumatic brain injury |
| AU2017322708A1 (en) | 2016-09-12 | 2019-03-21 | University Of South Florida | Neuroregeneration improved by ketone |
| DK3558280T3 (da) | 2016-12-21 | 2023-08-21 | Univ Kinderspital Beider Basel | Forebyggelse og behandling af migræne |
-
2016
- 2016-12-23 US US15/389,828 patent/US20180177753A1/en not_active Abandoned
-
2017
- 2017-11-30 CN CN201780078046.7A patent/CN110167637B/zh active Active
- 2017-11-30 ES ES17884757T patent/ES2962879T3/es active Active
- 2017-11-30 PT PT178847570T patent/PT3558458T/pt unknown
- 2017-11-30 KR KR1020197020923A patent/KR102390608B1/ko active Active
- 2017-11-30 MX MX2019006844A patent/MX389468B/es unknown
- 2017-11-30 CA CA3046350A patent/CA3046350C/en active Active
- 2017-11-30 BR BR112019012431A patent/BR112019012431A2/pt not_active Application Discontinuation
- 2017-11-30 JP JP2019534701A patent/JP7108320B2/ja active Active
- 2017-11-30 WO PCT/US2017/063832 patent/WO2018118369A1/en not_active Ceased
- 2017-11-30 IL IL267540A patent/IL267540B/en unknown
- 2017-11-30 MY MYPI2019003609A patent/MY190308A/en unknown
- 2017-11-30 EP EP17884757.0A patent/EP3558458B1/en active Active
-
2018
- 2018-12-14 US US16/220,365 patent/US10792269B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3046350A1 (en) | 2018-06-28 |
| JP7108320B2 (ja) | 2022-07-28 |
| BR112019012431A2 (pt) | 2020-04-14 |
| EP3558458B1 (en) | 2023-10-18 |
| US10792269B2 (en) | 2020-10-06 |
| MX2019006844A (es) | 2019-08-16 |
| US20180177753A1 (en) | 2018-06-28 |
| PT3558458T (pt) | 2023-11-27 |
| MY190308A (en) | 2022-04-13 |
| IL267540B (en) | 2022-07-01 |
| EP3558458A1 (en) | 2019-10-30 |
| WO2018118369A1 (en) | 2018-06-28 |
| CN110167637A (zh) | 2019-08-23 |
| KR102390608B1 (ko) | 2022-04-25 |
| CN110167637B (zh) | 2023-03-14 |
| KR20190099465A (ko) | 2019-08-27 |
| EP3558458A4 (en) | 2020-08-12 |
| IL267540A (en) | 2019-08-29 |
| JP2020502250A (ja) | 2020-01-23 |
| ES2962879T3 (es) | 2024-03-21 |
| MX389468B (es) | 2025-03-20 |
| US20190117612A1 (en) | 2019-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3046350C (en) | Glyceryl 3-hydroxybutyrates for migraine symptom management | |
| US11638702B2 (en) | Glyceryl 3-hydroxybutyrates for traumatic brain injury | |
| EP0637957B1 (de) | Verwendung einer omega-3-fettsäuren enthaltenden emulsion zur herstellung eines parenteral zu verabreichenden arzneimittels zur behandlung von entzündlichen erkrankungen | |
| US20070259037A1 (en) | Method and composition for treatment of inflammatory conditions | |
| CN103458893B (zh) | Sn‑1(3)单酰基甘油酯和脂质吸收 | |
| AU2012235869B2 (en) | Compositions for the treatment of neurologic disorders | |
| JP4986321B2 (ja) | 炎症性状態処置のための方法および組成物 | |
| JPH06172169A (ja) | 脂肪酸治療 | |
| JP2014527029A (ja) | 酸化ストレスの低減におけるｄｈａ及びｅｐａ | |
| JP7608707B2 (ja) | 近視進行抑制剤、機能性食品及び眼科用組成物 | |
| CN116490181A (zh) | 在人中施用β-羟基丁酸和相关化合物用于治疗和/或预防呼吸道疾病 | |
| HK40012930B (en) | Glyceryl 3-hydroxybutyrates for migraine symptom management | |
| HK40012930A (en) | Glyceryl 3-hydroxybutyrates for migraine symptom management | |
| JPH06271464A (ja) | 消化器系障害の予防または治療用アラキドン酸含有組成物 | |
| CHOW | Role of vitamins in lipid metabolism | |
| EP1147769A2 (de) | Verwendung von mehrfach ungesättigten Fettsäuren, insbesondere Omega-3-Fettsäuren, zur Behandlung von Enuresis und Inkontinenz | |
| HK40012461A (en) | Glyceryl 3-hydroxybutyrates for traumatic brain injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210902 |
|
| EEER | Examination request |
Effective date: 20210902 |
|
| EEER | Examination request |
Effective date: 20210902 |
|
| EEER | Examination request |
Effective date: 20210902 |
|
| EEER | Examination request |
Effective date: 20210902 |